Hunfeld, N.G.

study subject pantoprazole intragastric effect omeprazole intragastric ph genotype esomeprazole treatment aliment pharmacol pantoprazole 40 mg pharmacol signi day 1 *1/*1 mutation *1/*17 therapy percentage level esomeprazole 40 mg administration pharmacokinetic cyp 2c baseline haga teaching hospital signi ficantly pylori *1/*2 period caucasian aliment pylori-negative value ficant increase acid-inhibitory effect patient wt ⁄ wt cyp 2c genotype evidence acid-inhibitory population study b day 6 lansoprazole proton inhibitor metabolism acid production 24- *2/*17 ficantly cyp 2c polymorphism rebound acid hypersecretion acid-inhibition result ppi treatment *2/*2 table omeprazole 20 mg gastrin acidity *17 difference rebound dosing helicobacter hospital acid secretion lansoprazole 15 mg 24- h period publishing blackwell signi ficant acid-inhibition pylori status pylori-negative subjects polymorphism pharmacodynamic